Peptides, scored by the evidence
See which peptides the evidence backs, what each is researched for, and its US status.
- 58BioHarmony scores
- 95compounds
- Everyentry sourced
95 compounds, ranked by score
StatusVerdictGoal
- 7.4Thymosin Alpha-1Thymosin Alpha-1 is a 28-amino-acid thymic peptide with strongest evidence in immune-compromised and hospital-adjacent settings: Cao 2024 pooled 39 acute COPD…
- 7.2GHK-Cu (Copper Peptide)GHK-Cu is a human copper-binding tripeptide with the best evidence for topical skin repair and wound healing, including Mulder 1994 diabetic ulcer data showing 98.5%…
- 7.1SemaxSemax is a Russian-developed ACTH 4-7 + PGP heptapeptide with the strongest human signal in post-stroke recovery, including a 110-patient Gusev et al.
- 6.9Thymosin Beta-4 (Full)Thymosin beta-4 is the native 43-amino-acid peptide that promotes tissue repair via actin-sequestering and the Ac-SDKP repair axis.
- 6.8Gonadorelin (GnRH)Gonadorelin is synthetic GnRH, a decapeptide that tells the pituitary to release LH and FSH.
- 6.8SelankSelank is a synthetic tuftsin-derived heptapeptide studied as a non-sedating anxiolytic.
- 6.7ARA-290ARA-290 (cibinetide) is an EPO-derived peptide that activates the innate repair receptor to regrow small nerve fibers without EPO's blood effects.
- 6.7Epitalon (Epithalon)Epitalon is a synthetic AEDG tetrapeptide with in vitro telomerase and telomere data, animal lifespan signals, and Russian pineal-peptide melatonin studies.
- 6.6TB-500 (Thymosin Beta-4 Fragment)TB-500 is a synthetic LKKTETQ fragment marketed for soft-tissue repair, but most human evidence is on full-length topical thymosin beta-4: Sosne 2023 reported corneal…
- 6.6ThymulinThymulin (zinc-thymulin) is a chemically defined, zinc-dependent thymic nonapeptide hormone with deep classical immunology behind it but no modern human trial of the…
- 6.5AHK-Cu (Copper Tripeptide)AHK-Cu is a topical copper tripeptide, Alanine-Histidine-Lysine plus copper, marketed for hair growth.
- 6.5BPC-157BPC-157 is a 15-amino-acid gastric peptide fragment with consistent preclinical repair data, including a 2025 sports-medicine systematic review of 36 studies with 35…
- 6.5Kisspeptin-10Kisspeptin-10 is an investigational reproductive neuropeptide that activates the HPG axis through the KISS1R receptor.
- 6.5OxytocinIntranasal oxytocin is the endogenous bonding hormone used off-label as a nasal spray for social connection, anxiety, and libido.
- 6.4KPV (Lysine-Proline-Valine)KPV is a three-amino-acid alpha-MSH fragment that reduced inflammation in mouse colitis models through PepT1 uptake and NF-kB pathway suppression, but it still has zero…
- 6.4PinealonPinealon (Glu-Asp-Arg, or EDR) is a synthetic Khavinson tripeptide marketed for neuroprotection and cognition.
- 6.3CerebrolysinCerebrolysin is a porcine brain-derived peptide mixture given by IV or IM infusion.
- 6.2IpamorelinIpamorelin is a selective growth-hormone secretagogue with strong receptor selectivity but almost no human efficacy data: its only completed human efficacy trial…
- 6.2Melanotan IMelanotan I is most defensible for photoprotection in EPP and planned UV exposure, with Langendonk 2015 reporting 69.4 vs 40.8 hours of pain-free sun exposure in the US…
- 6.2SNAP-8SNAP-8 (acetyl octapeptide-3) is a topical cosmetic peptide sold as a Botox alternative.
- 6.1TirzepatideTirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor agonist with unusually large weight-loss and glycemic effects.
- 6.0DSIP (Delta Sleep Inducing Peptide)DSIP (Delta Sleep-Inducing Peptide) is a naturally-occurring nonapeptide whose famous name oversells it.
- 6.0MOTS-cMOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway.
- 6.0SS-31 (Elamipretide)SS-31 (elamipretide) is a mitochondria-targeting tetrapeptide that binds cardiolipin.
- 6.0TesamorelinTesamorelin is a stabilized GHRH analog that reduced visceral adipose tissue in the landmark Falutz 2007 HIV lipodystrophy Phase 3 trial and has newer support for…
- 5.9Semaglutide (GLP-1 Agonist)Semaglutide is a prescription GLP-1 receptor agonist that produced 14.9% mean weight loss in STEP-1 and cut 3-point MACE by 20% in SELECT, but the 5.5-6.0/10 score holds…
- 5.9SermorelinSermorelin (GHRH 1-29) is a short-acting peptide that prompts your own pituitary to release growth hormone, and it is the only one in its class with a former FDA…
- 5.9ThymalinThymalin is a bovine-thymus peptide extract studied for immune restoration and aging.
- 5.9VIP (Vasoactive Intestinal Peptide)VIP, or vasoactive intestinal peptide, is the endogenous neuropeptide whose synthetic form is aviptadil, used off-label for anti-inflammatory, immune, respiratory, and…
- 5.8CagrilintideCagrilintide (AM833) is a long-acting amylin receptor analogue that drove about 11.8 percent weight loss as monotherapy at 68 weeks in REDEFINE 1 per Garvey 2025, with…
- 5.8CJC-1295 No DAC (Mod GRF 1-29)CJC-1295 No DAC (Mod GRF 1-29) is a short-acting GHRH peptide, almost always stacked with ipamorelin, that prompts a pulse of your own growth hormone.
- 5.8GHRP-2 (Pralmorelin)GHRP-2 (pralmorelin) is a ghrelin-receptor peptide that drives a strong growth-hormone pulse, approved in Japan since 2004 as a diagnostic test.
- 5.8HumaninHumanin is a 24-amino-acid mitochondrial-derived peptide that declines with age and runs much higher in children of centenarians, per Yen 2020, but it scores Neutral…
- 5.8OrforglipronOrforglipron (Foundayo) is the first FDA-approved non-peptide oral GLP-1 pill, cleared for obesity in April 2026.
- 5.7VilonVilon is the Lysine-Glutamic acid (KE) dipeptide from Vladimir Khavinson's bioregulator program, sold for immune restoration and anti-aging.
- 5.6MazdutideMazdutide (IBI362) is the first GLP-1 plus glucagon dual agonist approved anywhere, cleared in China for obesity in June 2025.
- 5.6RetatrutideRetatrutide is Lilly's investigational once-weekly GLP-1/GIP/glucagon triple agonist.
- 5.4GHRP-6GHRP-6 is a synthetic peptide that activates the ghrelin receptor to release a pulse of your own growth hormone.
- 5.4PT-141 (Bremelanotide)PT-141 (bremelanotide) is the only FDA-approved drug for low sexual desire in premenopausal women (Vyleesi, 2019).
- 5.3VK2735VK2735 is an investigational dual GLP-1 and GIP receptor agonist from Viking Therapeutics that produced about 14.7 percent weight loss at 13 weeks in its peer-reviewed…
- 5.2LiraglutideLiraglutide is a once-daily prescription GLP-1 receptor agonist. In the 3,731-person SCALE trial, 3.0 mg with lifestyle counseling produced 8.4 kg mean weight loss…
- 5.2NAD+NAD+ (Direct) is the central redox coenzyme given by IV, injection, sublingual, or intranasal route, and it scores 5.0-5.5/10 because the human evidence is a single…
- 5.1CagriSemaCagriSema is an investigational once-weekly amylin plus GLP-1 injectable that produced about 22.7% weight loss on-treatment in REDEFINE 1, per Garvey 2025 in NEJM.
- 5.1SurvodutideSurvodutide (BI 456906) is an investigational once-weekly GLP-1 and glucagon dual agonist that drove up to 16.6% weight loss in Phase 3, per the Boehringer Ingelheim…
- 5.0BAM15BAM15 is an experimental mitochondrial uncoupler that reversed diet-induced obesity and insulin resistance in mice without raising body temperature, the effect that made…
- 5.0P21 (P021)P21 (P021) is a CNTF-derived peptidomimetic that crosses the blood-brain barrier and, in mice, raises BDNF, lifts hippocampal neurogenesis, and lowers tau pathology in…
- 5.0PE-22-28 (Spadin)PE-22-28 is a synthetic spadin analogue that blocks the TREK-1 potassium channel, a target with a clean and well-characterized link to fast-acting antidepressant effects…
- 5.0TesofensineTesofensine is a small-molecule triple monoamine reuptake inhibitor that produced strong Phase 2 weight loss for obesity, about 9 to 11 percent at 24 weeks per Astrup…
- 4.95-Amino-1MQ5-Amino-1MQ is a synthetic NNMT-inhibitor research compound that cut fat mass in obese mice and raised NAD+ in cultured fat cells (Neelakantan 2018), but it has zero…
- 4.9Ibutamoren (MK-677)MK-677 (ibutamoren) is an oral, once-daily growth-hormone secretagogue that raises IGF-1 by about 50 to 97 percent and adds roughly 1.1 kg of fat-free mass, per the Nass…
- 4.7SLU-PP-332SLU-PP-332 is a synthetic pan-ERR agonist developed in the Thomas Burris lab. Billon et al.
- 4.6LL-37 (Cathelicidin)LL-37 (Cathelicidin) is the only human cathelicidin antimicrobial peptide, with a rich antimicrobial and wound-healing mechanism but thin human therapy data: one small…
- 4.6Pentosan Polysulfate (PPS)Pentosan polysulfate (oral Elmiron) is an FDA-approved sulfated polysaccharide drug for interstitial cystitis bladder pain, sometimes used off-label for joints.
- 4.5Melanotan IIMelanotan II is a fast tanning and sexual-response peptide with a harsher safety tradeoff; Nelson 2012 reported rhabdomyolysis after a 6 mg injection.
- 4.4CJC-1295 DACCJC-1295 with DAC is the long-acting form, dosed about weekly, that keeps growth hormone elevated for 6 to 8 days.
- 4.3DihexaDihexa is a gray-market angiotensin IV analog with rodent synaptogenesis and memory data, including McCoy 2013 and Sun 2021, but zero human trials, no human…
- 4.1FOX04-DRIFOXO4-DRI is a designed senolytic peptide that kills senescent cells by breaking the FOXO4 to p53 bond, famous for restoring fur and kidney function in aged mice per…
- 3.0AOD-9604AOD-9604 is a human growth hormone fragment (hGH 176 to 191) marketed for fat loss, but its only controlled human weight-loss program failed to beat placebo, per the…
- Abaloparatide (Tymlos)FDA-approved abaloparatide is marketed as Tymlos for specified women and men with osteoporosis at high fracture risk or who have failed or cannot tolerate other therapy.
- ATX-304 (O-304)Amplifier Therapeutics describes ATX-304, also known as O-304, as an oral small-molecule pan-AMPK activator in Phase 2 development.
- B7-33B7-33 is a preclinical single-chain relaxin-family peptide agonist studied for selective antifibrotic signaling in animal models.
- Berobenatide (MET-097i / PF-08653944)Pfizer describes berobenatide, formerly MET-097i, as an investigational ultra-long-acting GLP-1 receptor agonist.
- Calcitonin SalmonFDA-approved calcitonin salmon products exist in nasal and injectable formulations for product-specific bone and calcium disorders.
- DesmopressinFDA-approved desmopressin formulations exist for product-specific uses including central diabetes insipidus and specified bleeding disorders; routes and strengths are…
- Dulaglutide (Trulicity)FDA-approved dulaglutide is marketed as Trulicity for improving glycemic control in adults and children 10 years and older with type 2 diabetes, with additional labeled…
- Enicepatide (CT-388)Roche describes enicepatide, formerly CT-388, as an investigational GLP-1 and GIP dual receptor agonist.
- ExenatideFDA-approved exenatide products exist for improving glycemic control in specified patients with type 2 diabetes.
- GlucagonMultiple FDA-approved glucagon rescue products exist for severe hypoglycemia. Formulations include ready-to-use solutions and products requiring preparation, with…
- Goserelin (Zoladex)FDA-approved goserelin is marketed as Zoladex implants for product-specific uses in prostate cancer, breast cancer, endometriosis, and endometrial thinning.
- Histrelin (Supprelin LA)FDA-approved histrelin is marketed as Supprelin LA, a 12-month implant for children with central precocious puberty.
- Icatibant (Firazyr)FDA-approved icatibant is marketed as Firazyr for treatment of acute hereditary angioedema attacks in adults 18 years and older.
- LanreotideFDA-approved lanreotide products exist for long-term treatment of acromegaly and for specified gastroenteropancreatic neuroendocrine tumors.
- LeuprolideMultiple FDA-approved leuprolide formulations exist. Their indications, release periods, doses, and preparation requirements are product-specific and not interchangeable.
- Linaclotide (Linzess)FDA-approved linaclotide is marketed as Linzess for irritable bowel syndrome with constipation and chronic idiopathic constipation, with age- and indication-specific…
- LixisenatideLixisenatide is a component of FDA-approved Soliqua 100/33, a fixed-ratio insulin glargine and lixisenatide product for improving glycemic control in adults with type 2…
- Maridebart Cafraglutide (MariTide)Amgen describes MariTide (maridebart cafraglutide) as an investigational antibody-peptide conjugate in an ongoing phase 3 obesity program.
- Navepegritide (Yuviwel)FDA granted accelerated approval to Yuviwel (navepegritide) in February 2026 for certain pediatric patients with achondroplasia; continued approval depends on…
- OctreotideFDA-approved octreotide products exist for acromegaly and severe diarrhea or flushing associated with specified tumors; dosing and preparation vary by formulation.
- P110P110 is a preclinical peptide inhibitor of the stress-associated Drp1-Fis1 interaction. Recent animal and cell studies do not establish human safety or effectiveness.
- Pasireotide (Signifor)FDA-approved pasireotide is marketed as Signifor for specified adults with Cushing disease; a long-acting formulation has a separate label for specified uses.
- PEG-MGFFDA says compounded PEG-MGF may pose immunogenicity, impurity, and characterization risks and that it has identified no human exposure data for PEG-MGF administered by…
- PemvidutideAltimmune describes pemvidutide as an investigational GLP-1 and glucagon dual receptor agonist.
- PetrelintideRoche and Zealand Pharma describe petrelintide as an investigational amylin analog.
- Plecanatide (Trulance)FDA-approved plecanatide is marketed as Trulance for chronic idiopathic constipation and irritable bowel syndrome with constipation in adults.
- Pramlintide (SymlinPen)Pramlintide was FDA approved as Symlin and SymlinPen as an adjunct to mealtime insulin in patients with type 1 or type 2 diabetes who have not achieved desired glucose…
- Rusfertide (PTG-300)FDA approved rusfertide as Mimrylo in August 2026 for the treatment of erythrocytosis in adults with polycythemia vera.
- Setmelanotide (Imcivree)FDA-approved setmelanotide is marketed as Imcivree for chronic weight management in patients with obesity caused by specific rare genetic conditions covered by the label.
- Teduglutide (Gattex)FDA-approved teduglutide is marketed as Gattex for adults and pediatric patients one year and older with short bowel syndrome who are dependent on parenteral support.
- TeriparatideFDA-approved teriparatide products exist for specified women and men with osteoporosis at high fracture risk and for glucocorticoid-associated osteoporosis in specified…
- Terlipressin (Terlivaz)FDA-approved terlipressin is marketed as Terlivaz to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function.
- Triptorelin (Trelstar)FDA-approved triptorelin is marketed as Trelstar depot formulations for palliative treatment of advanced prostate cancer, with product-specific dosing intervals.
- UBT251Novo Nordisk reports that a Phase 1a/2b trial has started for UBT251, an investigational triple agonist.
- Vosoritide (Voxzogo)FDA-approved vosoritide is marketed as Voxzogo to increase linear growth in pediatric patients with achondroplasia and open epiphyses.
- Zenagamtide (Amycretin)Novo Nordisk describes zenagamtide, formerly amycretin, as an investigational GLP-1 and amylin receptor agonist.
- Ziconotide (Prialt)FDA-approved ziconotide is marketed as Prialt for severe chronic pain in patients for whom intrathecal therapy is warranted and who are intolerant of or refractory to…
Where the evidence sits
58 scored compounds on one scale, from 0 to 10.
3 strong, 45 moderate, 10 limited.
The Ultimate Peptides Guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.